Mantle Cell Lymphoma
Conference Coverage
In mantle cell lymphoma, triple therapy proves too toxic
Combined idelalisib, lenalidomide, and rituximab proved excessively toxic for the treatment of relapsed and refractory mantle cell and follicular...
Conference Coverage
Newly diagnosed mantle cell lymphoma is ‘one of the hardest consultations’
NEW YORK – Maintenance therapy puts off life-disrupting autologous stem cell transplantation, perhaps for what may be several years, but relapse...
Article
MAGNIFY in relapsed/refractory mantle cell lymphoma
MAGNIFY is actively recruiting patients.
Feature
Unavoidable, random DNA replication errors are the most common cancer drivers
Up to two-thirds of the mutations that drive human cancers may be due to DNA replication errors in normally dividing stem cells, not by inherited...
Conference Coverage
Phase III trial: VZV protects auto-HCT patients
ORLANDO – An inactivated VZV vaccine for adults undergoing autologous hematopoietic stem cell transplantation has proven safe and effective.
From the Journals
For mantle cell lymphoma, VR-CAP beat R-CHOP
The difference was especially evident among patients who had a low- or medium-risk mantle cell lymphoma international prognostic index.
Conference Coverage
Ibrutinib, palbociclib yield durable complete responses in pretreated mantle cell lymphoma
SAN DIEGO – A “mechanism-based” combination of ibrutinib and palbociclib was reasonably well tolerated and induced complete responses in 44% of...
Conference Coverage
Bortezomib-based regimen led to durable remissions in mantle cell lymphoma
First-line therapy with bortezomib plus modified hyper-CVAD followed by rituximab maintenance induced durable remissions in mantle cell lymphoma...
Conference Coverage
Rituximab after ASCT boosted survival in mantle cell lymphoma
SAN DIEGO – Maintenance therapy every other month with rituximab significantly prolonged event-free and overall survival after autologous stem...
Video
VIDEO: First multicenter trial of CAR T cells shows response in DLBCL
SAN DIEGO - Aggressive, refractory non-Hodgkin lymphomas responded to anti-CD19 chimeric antigen receptor T cells in ZUMA-1, the first...
Conference Coverage
Chemo-free induction regimen shines in MCL
SAN DIEGO – A chemotherapy-free induction regimen of ibrutinib and rituximab was well tolerated and achieved an overall response rate of 100%...